Typhoid

A single dose of a typhoid conjugate vaccine provided protection for at least 4 years among children aged 9 months to 12 years enrolled in a phase 3 trial in Malawi, according to results published in The Lancet.

Routine use of a typhoid conjugate vaccine with a catch-up campaign through age 15 years could prevent approximately 67 million cases and 826,000 deaths caused by typhoid fever over 10 years, according to a study.

As typhoid fever becomes increasingly resistant to antibiotics, a study published recently in The New England Journal of Medicine showed that a conjugate vaccine for the disease proved effective for Malawi’s younger population.

Typhoid conjugate vaccine is safe and effective in children when given with meningococcal A vaccine as part of routine immunization.

A single-dose typhoid conjugate vaccine effectively reduced typhoid in children aged 9 months to 16 years by more than 81% during a phase 3 trial in Nepal, according to results published in The New England Journal of Medicine.